Nicholas Piramal to offer a one-stop-shop
Mumbai-based Nicholas Piramal India Limited (NPIL), the country's fourth largest pharma company, has worked out a new 'export model' providing global companies with an end-to-end outsourcing solution across the pharmaceutical life cycle, from custom chemical synthesis, bulk intermediates and APIs to formulations.
Mumbai-based Nicholas Piramal India Limited (NPIL), the country's fourth largest pharma company, has worked out a new 'export model' providing global companies with an end-to-end outsourcing solution across the pharmaceutical life cycle, from custom chemical synthesis, bulk intermediates and APIs to formulations.
The company's manufacturing plants at Pithampur and Hyderabad, which have been dedicated to custom manufacturing, have already received US FDA quality approvals. In order to service the European and US majors, the company has also set up subsidiaries in these regions.
To start with, NPIL has signed an agreement with Advanced Medical Optics in the US, to manufacture select eye-care products for the global market. The company is also currently in talks with other major multinational companies. Building a strong base for research services, the company is also investing Rs 700m for setting up a new r&d centre in Mumbai.
